Important note: Information in this article was accurate in November 2009. The state of the art may have changed since the publication date.
Reduced etravirine levels after direct switch from efavirenz
HIV Treat Bull - 2009 Nov/Dec;10(11/12): 28
This study in 25 healthy volunteers assessed the pharmacokinetics of etravirine (400 mg once daily and 200 mg twice daily) without and with a preceding efavirenz intake period (600 mg once daily for 14 days). Etravirine pharmacokinetics were assessed before and after efavirenz intake.
Steady state etravirine pharmacokinetic parameters were significantly lower after efavirenz intake in the once daily and twice daily arms. Etravirine AUC,Cmax and Ctrough when given once daily decreased by 29%, 22% and 33%, respectively.
When given twice daily, etravirine AUC, Cmax and Ctrough decreased by 28%, 21% and 37%, respectively. All subjects had detectable efavirenz concentrations 7 days after stopping efavirenz intake; 5/25 had concentrations above the suggested minimum effective concentration of 1000 ng/ml.
The authors conclude that the induction effect of efavirenz persists for at least 2 weeks after stopping drug intake, but that the decrease in etravirine is not likely to be clinically significant. However, further clinical data are warranted.
Ref: Boffito M, Jackson A, Lamorde M, et al. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. J Acquir Immune Defic Syndr, 2009 Oct, 52(2): 222-227.
2009-11-10
IB2009-11-28
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in November 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.